Foghorn Therapeutics (FHTX+) Expects High Returns On Capital Employed in 2023
March 22, 2023
Trending News 🌥️
Foghorn Therapeutics ($NASDAQ:FHTX) (NASDAQ:FHTX) is a biotechnology company focused on discovering and developing treatments for cancer and other serious diseases. Investors are now looking ahead to Foghorn Therapeutics (FHTX+) expected returns on capital employed in 2023. The company offers free alerts to investors to gain insight into return on capital employed for Foghorn Therapeutics (NASDAQ:FHTX). Through these alerts, investors can stay updated with Foghorn Therapeutics earnings perspective. This is due to the strong pipeline of product candidates in development and the increasing research and development spending by Foghorn Therapeutics. The company has been actively investing in new technologies and drug discovery efforts, which could lead to higher returns in the future.
Furthermore, investors will benefit from Foghorn Therapeutics expanding presence in multiple therapeutic areas. By signing up for free alerts, investors can stay updated on Foghorn’s progress towards achieving its high return on capital employed target in 2023. With this information at hand, investors can make better and more informed decisions on how to invest their capital. This is due to the strong pipeline of product candidates, increasing research and development spending, and expanding presence in multiple therapeutic areas. Through its free alerts, investors can stay updated on the company’s progress and make better investment decisions.
Price History
Foghorn Therapeutics (FHTX+) has seen mostly negative news coverage so far. On Wednesday, FOGHORN THERAPEUTICS stock opened at $5.1 and closed at $4.9, a 5.8% decrease from the previous closing price of 5.2. This optimism is backed by their research and development of novel treatments for difficult to treat diseases. Their focus on creating safe, effective treatments and therapies will help drive their growth potential in the coming year. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Foghorn Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 19.23 | -108.88 | -566.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Foghorn Therapeutics. More…
| Operations | Investing | Financing |
| 193.61 | -244.32 | 1.76 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Foghorn Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 404.88 | 404.77 | 0 |
Key Ratios Snapshot
Some of the financial key ratios for Foghorn Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | -566.3% |
| FCF Margin | ROE | ROA |
| 1000.6% | -557.0% | -16.8% |
Analysis
GoodWhale recently performed an analysis of FOGHORN THERAPEUTICS‘s wellbeing. The results of our assessment placed the company in the medium risk category of our Risk Rating system, indicating that FOGHORN THERAPEUTICS is a moderately safe investment in terms of financial and business aspects. We also detected two risk warnings in the balance sheet and cashflow statement of FOGHORN THERAPEUTICS. For more detailed information about these warnings, we invite interested parties to register with us to gain access to our report. Our report will provide you with a comprehensive overview of FOGHORN THERAPEUTICS’s current financial and business situation. More…
Peers
With each of these companies striving to develop innovative treatments and therapies, the race to stay ahead of the competition is ever-present.
– Omega Therapeutics Inc ($NASDAQ:OMGA)
Omega Therapeutics Inc is a biopharmaceutical company based in San Francisco that focuses on the research and development of novel therapies to address unmet needs in immunology. As of 2023, Omega Therapeutics has a market capitalization of 335.71M, which reflects the company’s current value in the public markets. Additionally, Omega Therapeutics has a Return on Equity of -48.06%, which indicates that the shareholders’ investment in the company has resulted in a net loss in the past year.
– TME Pharma NV ($BER:0N6A)
TME Pharma NV is a biopharmaceutical company based in Belgium that is focused on developing innovative treatments for chronic and rare diseases. As of 2023, the company has a market cap of 1.59M. TME Pharma’s Return on Equity (ROE) is -271.38%, which suggests that the company has struggled to generate profits from its investments. Despite this, the company is developing a strong pipeline of promising new treatments and could well see its market cap increase in the future.
– Shattuck Labs Inc ($NASDAQ:STTK)
Shattuck Labs Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel immunotherapies for the treatment of cancer and other diseases. It has a market cap of 122.25M as of 2023 and a negative Return on Equity (ROE) of -34.39%. The market cap indicates that the company is valued at over one hundred million dollars, while its negative ROE suggests that it has not had much success generating profits from its operations. Nevertheless, Shattuck Labs Inc remains dedicated to its mission of discovering and developing novel immunotherapies for cancer and other diseases.
Summary
Foghorn Therapeutics (FHTX+) is a stock that has received mostly negative news coverage, yet the company has forecasted high returns on its capital employed by 2023. Investors should perform their own due diligence when considering an investment in Foghorn Therapeutics. Analysts suggest that investors pay attention to important performance metrics such as the company’s revenue and profits, balance sheet, cash flow, and future earnings potential. As with any investment, investors should also assess the current market conditions, potential risks, and any other relevant factors before making a decision.
